What would a Shire buy look like for Pfizer, Amgen or AbbVie? Analysts lay out pros and cons

6th April 2018 Uncategorised 0

With Takeda weighing a Shire bid, other companies may be taking a hard look at the struggling biotech, too. Credit Suisse analysts have flagged just which companies might make a move and broken down what a deal with each could look like.

More: What would a Shire buy look like for Pfizer, Amgen or AbbVie? Analysts lay out pros and cons
Source: fierce